Related Experiment Videos
Murine cross-reactive T-cell epitopes of Neisseria meningitidis outer membrane proteins
M R Lifely1, M V Rogers, J Esdaile
1Department of Cell Biology, Wellcome Research Laboratories, Beckenham, Kent, UK.
Abstract:
Five non-covalent vaccines of outer membrane proteins (OMPs) complexed to capsular polysaccharide were prepared from Neisseria meningitidis serogroup B strains. Each vaccine contained distinct serotype (class 2/3) and subtype (class 1) OMPs. The cross-reactivity of the T-cell response to the meningococcal vaccine-associated proteins was examined in an in vitro T-cell proliferative assay, following antigenic priming of mice with one of these vaccines (MB6:P1.6) or with its purified class 1 (subtype P1.6) and class 2 (serotype 6) proteins. Cross-reactive T-cell epitopes were found in all five vaccine preparations on both the class 1 and class 2/3 OMPs. Priming of mice with the subtype P1.6 N-terminal peptide led to a significant but small increase in T-cell proliferation with the MB6:P1.6 vaccine.
Insights
This study investigated T-cell responses to meningococcal serogroup B vaccines. Cross-reactive T-cell epitopes were identified on outer membrane proteins (OMPs) in all tested vaccine preparations, indicating broad immune recognition.
Area of Science:
- Immunology
- Microbiology
- Vaccinology
Background:
- Neisseria meningitidis serogroup B poses a significant public health threat.
- Outer membrane proteins (OMPs) are key components of meningococcal vaccines.
- Understanding T-cell responses to OMPs is crucial for vaccine development.
Purpose of the Study:
- To examine the cross-reactivity of T-cell responses to meningococcal serogroup B vaccines.
- To identify cross-reactive T-cell epitopes on OMPs.
- To assess the impact of specific OMP components on T-cell proliferation.
Main Methods:
- Preparation of five non-covalent vaccines from Neisseria meningitidis serogroup B strains.
- Antigenic priming of mice with vaccine preparations or purified OMPs.
- In vitro T-cell proliferative assay to measure T-cell responses.
Main Results:
- Cross-reactive T-cell epitopes were detected on both class 1 and class 2/3 OMPs in all five vaccine preparations.
- Priming with a specific subtype P1.6 N-terminal peptide showed a small but significant increase in T-cell proliferation.
- Evidence of broad T-cell recognition across different OMP classes.
Conclusions:
- Meningococcal serogroup B vaccines containing OMPs elicit cross-reactive T-cell responses.
- The findings suggest potential for broader immune coverage with OMP-based vaccines.
- Further research into T-cell epitope mapping can optimize vaccine design.